Nochmal für diejenigen, die die letzten zwei Tage verschlafen haben:
- ehemalige Explorationsfirma (Thail, Burma, AUS)
- Aufkauf von DoctorGlobal.com (z.Zt. 60% mit Nachkauf/Rückgabeoption)
- Testläufe in Neuseeland und China erfolgreich
Hier die Meldung
TERREX R. NL (www.terrex.com.au)
Quarterly Report - 30 September 1999
HIGHLIGHTS
Acquisition of Global Doctor Ltd
Acquisition of a 60% interest in Global Doctor Ltd, a company which intends to participate in the
medical industry through the provision of internet communication services to link medical services users
with providers. The principal terms of the acquisition require the company to issue 26.25 million fully
paid ordinary shares and to fund the first $450,000 of expenditure to develop the business.
Mr Gavin Argyle, who was appointed to the board of the company during the quarter, has been
appointed chief executive officer of Global Doctor and has initiated a plan for the rapid development of
the business. Facilities are presently being completed in Perth and in two Asian cities in order to trial
the systems.
A successful technical trial has been completed of its video conferencing and telemedicine equipment
from its first clinic in Chengdu, the capital of Sichuan, China. In addition, key medical and
administrative appointments have been completed.
Mineral Exploration
Formal granting of three Prospecting Licences in Myanmar to Terrex and its joint venture partners.
Share Issues and New Constitution
Completion of two placements to raise a total of $1,575,000 and approval to change the status of the
Company (from "NL" to "Limited").
ACQUISITION OF INTEREST IN GLOBAL DOCTOR LTD
In August 1999 the company announced the acquisition of a 60% interest in the capital of Global Doctor Limited ("GDL"), a
company which intends to participate in the medical industry through the provision of internet communication services to
link medical services users with providers. The principal terms of the acquisition require the company to issue 26.25
million fully paid ordinary shares ("Vendor Shares") and to fund the first $450,000 of expenditure to develop the business.
Additional terms include:-
(i) A two year option to acquire an additional 20% of the issued capital of GDL. The consideration for
this additional interest shall be based on an independent valuation of GDL at the time the option is
exercised.
(ii) A first right of refusal over the remaining 20% of GDL shares.
(iii) The Vendor Shares will be subject to a voluntary escrow period of 12 months.
(iv) If the software acquired by the Company pursuant to the agreement is not operating satisfactorily
within 6 months, then one third of the Vendor Shares will be cancelled. In addition, if trials at two
overseas sites are not satisfactorily completed within 12 months, then one third of the Vendor Shares
will be cancelled (a total of two thirds of the Vendor Shares therefore being cancellable).
Following the completion of the acquisition of the interest in GDL, Mr Gavin Argyle was appointed a director of the
Company. Mr Argyle is CEO of GDL and is responsible for the commercialisation of GDL's business. Mr Argyle has
initiated a plan for the rapid development of the business. This presently involves the development of facilities being
completed in Perth and in two Asian cities in order to trial the systems.
GDL has successfully conducted a technical trial of its video conferencing and telemedicine equipment from its first clinic in
Chengdu, the capital of Sichuan, China. GDL has engaged clinical staff in Australia and China enabling delivery of a western
general practice service with Australian based doctors. GDL is currently in the process of seeking the necessary approvals
from the Chinese government for the Chengdu clinic. GDL proposes to set up its second clinic in Asia and GDL is in the
process of seeking the necessary government approvals, staff and offices.
- ehemalige Explorationsfirma (Thail, Burma, AUS)
- Aufkauf von DoctorGlobal.com (z.Zt. 60% mit Nachkauf/Rückgabeoption)
- Testläufe in Neuseeland und China erfolgreich
Hier die Meldung
TERREX R. NL (www.terrex.com.au)
Quarterly Report - 30 September 1999
HIGHLIGHTS
Acquisition of Global Doctor Ltd
Acquisition of a 60% interest in Global Doctor Ltd, a company which intends to participate in the
medical industry through the provision of internet communication services to link medical services users
with providers. The principal terms of the acquisition require the company to issue 26.25 million fully
paid ordinary shares and to fund the first $450,000 of expenditure to develop the business.
Mr Gavin Argyle, who was appointed to the board of the company during the quarter, has been
appointed chief executive officer of Global Doctor and has initiated a plan for the rapid development of
the business. Facilities are presently being completed in Perth and in two Asian cities in order to trial
the systems.
A successful technical trial has been completed of its video conferencing and telemedicine equipment
from its first clinic in Chengdu, the capital of Sichuan, China. In addition, key medical and
administrative appointments have been completed.
Mineral Exploration
Formal granting of three Prospecting Licences in Myanmar to Terrex and its joint venture partners.
Share Issues and New Constitution
Completion of two placements to raise a total of $1,575,000 and approval to change the status of the
Company (from "NL" to "Limited").
ACQUISITION OF INTEREST IN GLOBAL DOCTOR LTD
In August 1999 the company announced the acquisition of a 60% interest in the capital of Global Doctor Limited ("GDL"), a
company which intends to participate in the medical industry through the provision of internet communication services to
link medical services users with providers. The principal terms of the acquisition require the company to issue 26.25
million fully paid ordinary shares ("Vendor Shares") and to fund the first $450,000 of expenditure to develop the business.
Additional terms include:-
(i) A two year option to acquire an additional 20% of the issued capital of GDL. The consideration for
this additional interest shall be based on an independent valuation of GDL at the time the option is
exercised.
(ii) A first right of refusal over the remaining 20% of GDL shares.
(iii) The Vendor Shares will be subject to a voluntary escrow period of 12 months.
(iv) If the software acquired by the Company pursuant to the agreement is not operating satisfactorily
within 6 months, then one third of the Vendor Shares will be cancelled. In addition, if trials at two
overseas sites are not satisfactorily completed within 12 months, then one third of the Vendor Shares
will be cancelled (a total of two thirds of the Vendor Shares therefore being cancellable).
Following the completion of the acquisition of the interest in GDL, Mr Gavin Argyle was appointed a director of the
Company. Mr Argyle is CEO of GDL and is responsible for the commercialisation of GDL's business. Mr Argyle has
initiated a plan for the rapid development of the business. This presently involves the development of facilities being
completed in Perth and in two Asian cities in order to trial the systems.
GDL has successfully conducted a technical trial of its video conferencing and telemedicine equipment from its first clinic in
Chengdu, the capital of Sichuan, China. GDL has engaged clinical staff in Australia and China enabling delivery of a western
general practice service with Australian based doctors. GDL is currently in the process of seeking the necessary approvals
from the Chinese government for the Chengdu clinic. GDL proposes to set up its second clinic in Asia and GDL is in the
process of seeking the necessary government approvals, staff and offices.
